📣Today is Global #fattyliverday! We are joining Global Liver Institute to raise awareness about #fattyliverdisease in the United States. Join us and all our partners around the world as we raise awareness about this serious #liverdisease that is on the rise. #Gastroenterology #GI #LiverDisease #FattyLiverDisease #FattyLiver #MASH #MASLD

In Case You Missed It | At DDW 2026, we shared new data showing how a noninvasive, blood‑based Fibrosis Index Score can help rule in treatment‑eligible MASH (F2/F3) while ruling out cirrhosis (F4)—addressing a critical gap as fibrosis‑stage-specific therapies become available. Key highlights from the poster: ✅ Validated in a large, biopsy‑confirmed MASH cohort (N=1,036) ✅ Uses a multi‑analyte serum panel with a 0–100 algorithmic score ✅ Interval likelihood ratios provide clinically actionable ranges, not just binary cutoffs ✅ Strong discrimination for ruling in F2/F3 and ruling out F4 ✅Identifies a clear treatment‑eligible window where F2/F3 is favored and cirrhosis risk remains low These findings support noninvasive testing as a practical tool for broader screening, precise patient stratification and longitudinal monitoring in MASH. 📊 Learn more: prometheuslabs.com/near-term… #DDW2026 #MASH #NASH #Fibrosis #NonInvasiveDiagnostics #Hepatology #ClinicalResearch #PrecisionMedicine #Gastroenterology #IBD #GI #GIHealth #LiverDisease #FattyLiverDisease

Prometheus Laboratories is proud to support Take Steps for Crohn’s & Colitis, which is happening Saturday, June 14 in San Diego at NTC Park in Liberty Station. This event helps @CrohnsColitisFn raise funds to support the millions of individuals and families affected by Crohn’s disease and ulcerative colitis through research, education and critical patient programs. 🎗💜 Join us by donating or sharing this campaign to help drive impact where it matters most. 👉 Donate here: takesteps.crohnscolitisfound… #TakeSteps #TakeStepsEffect #CrohnsAndColitis #IBDAwareness #GiveBack

In Case You Missed It | At DDW 2026, new data showed that validated serological signatures can accurately identify inflammatory bowel disease (IBD) and distinguish Crohn’s disease (CD) from ulcerative colitis (UC) – in both adult and pediatric populations. Using a panel of anti‑microbial and autoantigen antibodies, researchers trained and validated models that demonstrated: ✅ Strong performance differentiating IBD vs non‑IBD (AUC ~0.85 in adults; 0.80 in pediatrics) ✅ High accuracy in stratifying UC vs CD, with especially robust results in pediatric cohorts (AUC up to 0.96) ✅ Clear serologic patterns: anti‑microbial antibodies supporting CD classification, while pANCA/PR3/αvβ6 signatures were enriched in UC and colonic CD These findings highlight the potential of serologic profiling to enable earlier diagnosis, improve disease classification and support future risk stratification. 📄 Unique Serological Signatures Enable the Diagnosis and Stratification of IBD: eposters.ddw.org/ddw/2026/dd… #DDW2026 #IBD #CrohnsDisease #UlcerativeColitis #Gastroenterology #PrecisionMedicine

Prometheus has been at the forefront of noninvasive liver fibrosis assessment for more than two decades. Today, that legacy continues. Guided by translational research presented at DDW® 2026, we are developing a next‑generation blood‑based test to better support identification and longitudinal assessment of treatment‑eligible MASH patients in a rapidly evolving care landscape. Often asymptomatic, MASH affects up to 20 million people in the United States, with prevalence rising alongside obesity and type 2 diabetes. Providing a noninvasive blood-based solution will help enable these patients to be identified, often more timely and cost-effectively than biopsy or resource intensive-imaging, so treatment can be initiated before MASH progresses to cirrhosis. Read the press release: prometheuslabs.com/near-term… #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #LiverDisease #FattyLiverDisease #MASH #PrecisionMedicine

Prometheus Laboratories is proud to support Take Steps for Crohn’s & Colitis, helping raise awareness and critical funds for @CrohnsColitisFn. Our team is stepping up to make a difference for the millions of individuals and families affected by inflammatory bowel disease (IBD). 🎗💜 Join us by donating or sharing this campaign to help drive impact where it matters most. 👉 Donate here: takesteps.crohnscolitisfound… #TakeSteps #TakeStepsEffect #CrohnsAndColitis #IBDAwareness #GiveBack

Today is World IBD Day (May 19)—a moment to stand with the 10 million people worldwide living with inflammatory bowel disease. At Prometheus Laboratories, we support patients with Crohn’s disease and ulcerative colitis by equipping clinicians with advanced diagnostic insights that help bring clarity to a complex disease. Our precision-guided tests play a critical role in helping HCPs make an accurate diagnosis and personalize treatment decisions. On World IBD Day, we join the global community in raising awareness, reducing stigma, and advocating for earlier diagnosis and better outcomes for all those affected by IBD. 💜 Together, knowledge can change the course of care. #WorldIBDDay #WorldIBDDay2026 #IBDHasNoBorders #IBD #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis #Gastroenterology #GIHealth #PrecisionMedicine

Did You Know? | 40% of PredictrPK ADA test results led to therapy adjustments to optimize treatment. PredictrPK tests provide objective, individualized evidence to improve the efficiency and precision of biologic optimization, making dosing changes simpler by reducing unnecessary step adjustments in support of obtaining and maintaining response persistence. 🔗Learn more: prometheuslabs.com/ada-maint… #Gastroenterology #GITwitter #IBD #IBDTwitter #GI #GIHealth #PrecisionMedicine

That’s a wrap on #DDW2026! Thank you to everyone who stopped by our booth to connect with our team and see what’s next in precision diagnostics. We were excited to share how we’re continuing to innovate across GI—including a first look at updates to our liver testing as we expand non-invasive tools to support HCPs managing patients with metabolic dysfunction–associated steatohepatitis (MASH). The conversations, curiosity and enthusiasm made this year unforgettable. We’ll see you next year in Washington D.C.! #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis #LiverDisease #FattyLiverDisease #MASLD

IBD Precis® is the latest evolution of our diagnostic test that gives providers clarity to differentiate IBD from non-IBD and Crohn’s disease (CD) from ulcerative colitis (UC). We’ve added novel markers, anti-integrin (αvβ6) and anti-PR3, to improve its diagnostic accuracy and risk stratification. If you’re at #DDW2026, stop by booth 2123 to discuss what’s new. Or you can learn more on our website: prometheuslabs.com/about-ibd… #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis

Here’s where you can find Prometheus Laboratories’ latest research today at #DDW2026… See it in the Poster Hall today: ⭐ (Mo1630) Weight-Dependent Variability in Infliximab Clearance Across Pediatric and Adult IBD: Real World Pharmacokinetic Insights – authored by Dr. Elizabeth Spencer Scan the QR code to learn more and, if you missed it, be sure to visit our page to see more research we shared during DDW! #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis

Our tests for detecting, staging and monitoring liver fibrosis are evolving with new data presented earlier today at DDW! If you’re at DDW, stop by booth 2321 to learn what we have in the pipeline for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Read the full announcement here: prometheuslabs.com/near-term… #DDW2026 #Gastroenterology #GITwitter #IBD #IBDTwitter #GI #GIHealth #MASH #LiverDisease #FattyLiverDisease #MASLD

Here’s where you can find Prometheus Laboratories’ latest research at #DDW2026… See it in the Poster Hall today: ❇️ (Su2029) Non-Invasive Testing to Rule-In Moderate to Severe Fibrosis While Ruling Out Cirrhosis for Therapeutic Intervention in Metabolic Dysfunction-Associated Steatohepatitis – authored by Dr. Rohit Loomba ❇️ (Su1523) Unique Serological Signatures Enable the Diagnosis and Stratification of Inflammatory Bowel Disease – authored by Dr. Jean-Frederic Colombel Scan the QR codes to learn more or read the full announcement: prometheuslabs.com/near-term… #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis #LiverDisease #FattyLiverDisease #MASLD

IBD Precis® has officially replaced IBD sgi Diagnostic, our previous diagnostic test for inflammatory bowel disease (IBD). For patterns consistent with IBD, IBD Precis is 92% sensitive and 73% specific for differentiating Crohn’s disease (CD) from ulcerative colitis (UC).* Stop by DDW booth # 2321 to hear about the novel markers we’ve added to improve diagnostic accuracy or visit our website to learn more: prometheuslabs.com/about-ibd… #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis *Data on file

Here’s where you can find Prometheus Laboratories’ latest research at #DDW2026… See it in the Poster Hall today: ✨️(Sa1517) Clearance, In Combination with Drug Concentrations is Associated with a Non-Invasive Test of Endoscopic Inflammation Across Multiple Monoclonal Antibodies in Inflammatory Bowel Disease – authored by Dr. Adam Cheifetz ✨️(Sa1494) Precision-Guided Dosing of Infliximab: The BEST (Bayesian Estimates Sustaining Trough) Study for Sustained Remission and Quality of Life in Inflammatory Bowel Disease – authored by Dr. Tina Deyhim Scan the QR codes to learn more or read the full announcement: prometheuslabs.com/drug-clea… #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis

If you’re in Chicago, come see us at DDW booth 2123. We have a lot of exciting things to share! ⭐ Our new test, IBD Precis®, leverages novel biomarkers that strengthen diagnostic confidence by enhancing disease identification and differentiation. Beyond distinguishing IBD from non-IBD and Crohn’s disease from ulcerative colitis, these markers support risk stratification and offer non-invasive insight into potential colonic and/or ileal involvement. ⭐ Precision-guided dosing with drug clearance assessment for infliximab, adalimumab, vedolizumab and ustekinumab in IBD patients. ⭐ Our plans to support HCPs managing patients with metabolic dysfunction-associated steatohepatitis (MASH) with a new non-invasive test. #DDW2026 #Gastroenterology #IBD #GI #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis #LiverDisease #FattyLiverDisease #MASLD #MASH

Children with IBD have evolving needs, which is why new NASPGHAN clinical guidelines confirm that better outcomes are achieved when therapeutic plans are tailored to each child. PredictrPK simplifies personalized dosing by using patient data to generate tailored schedules, helping clinicians hit therapeutic targets early. Learn more: prometheuslabs.com/ifxinduct… #IBD #PediatricGI #InflammatoryBowelDisease #Gastroenterology #GITwitter #IBDTwitter #GI #GIHealth #PrecisionMedicine

🔬🧪 Happy #LabWeek2026! This week, we proudly recognize the incredible laboratory professionals at Prometheus Laboratories. While much of their work happens behind the scenes, the impact is front and center – driving insights, advancing science and helping improve outcomes for patients living with IBD and liver disease. 🚀 Their expertise, precision and commitment power everything we do. This week (and every week), we’re grateful for the dedication and excellence of our lab team – the true backbone of our mission. 👏 Thank you for all that you do!

How do you know whether an IBD patient will respond to an anti-TNF? Respondr TNF provides you with actionable information to determine their likelihood of response to anti-TNFs before the initiation of the first dose. Learn more about Respondr: prometheuslabs.com/respondr/ #Gastroenterology #GITwitter #IBD #IBDTwitter #GI #GIHealth

In Case You Missed It | Anti-PR3 may predict primary non-response to anti-TNFs A small study recently found that ⅔ of patients that were positive for anti-PR3 antibodies experienced primary non-response to anti-TNFs, compared to only ¼ of patients that were negative for anti-PR3. Learn More: pubmed.ncbi.nlm.nih.gov/4120… #Gastroenterology #GITwitter #IBD #IBDTwitter #GI #GIHealth #ulcerativecolitis